The rising problem of antimicrobial resistance in the intensive care unit

Abstract

Mainly due to its extremely vulnerable population of critically ill patients, and the high use of (invasive) procedures, the intensive care unit (ICU) is the epicenter of infections. These infections are associated with an important rise in morbidity, mortality, and healthcare costs. The additional problem of multidrug-resistant pathogens boosts the adverse impact of infections in ICUs. Several factors influence the rapid spread of multidrug-resistant pathogens in the ICU, e.g., new mutations, selection of resistant strains, and suboptimal infection control. Among gram-positive organisms, the most important resistant microorganisms in the ICU are currently methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In gram-negative bacteria, the resistance is mainly due to the rapid increase of extended-spectrum Beta-lactamases (ESBLs) in Klebsiella pneumonia, Escherichia coli, and Proteus species and high level third-generation cephalosporin Beta-lactamase resistance among Enterobacter spp. and Citrobacter spp., and multidrug resistance in Pseudomonas aeruginosa and Acinetobacter species. To conclude, additional efforts are needed in the future to slow down the emergence of antimicrobial resistance. Constant evaluation of current practice on basis of trends in MDR and antibiotic consumption patterns is essential to make progress in this problematic matter.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 56

1. 1.

   Marwick C Davey P Care bundles: the holy grail of infectious risk management in hospital?Curr Opin Infect Dis2009 22364369

   Not in our library10.1097/qco.0b013e32832e0736

2. 2.

   Hanberger H Garcia-Rodriguez JA Gobernado M Goossens H Nilsson LE Struelens MJ Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study GroupsJAMA1999 2816771

   Not in our library10.1001/jama.281.1.67

3. 3.

   Vincent JL Bihari DJ Suter PM Bruining HA White J Nicolas-Chanoin MH Wolff M Spencer RC Hemmer M The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory CommitteeJAMA1995 274639644

   Not in our library10.1001/jama.274.8.639

4. 4.

   Vandijck DM Depaemelaere M Labeau SO Depuydt PO Annemans L Buyle FM Oeyen S Colpaert KE Peleman RP Blot SI Decruyenaere JM Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infectionInt J Antimicrob Agents2008 31161165

   Not in our library10.1016/j.ijantimicag.2007.10.015

5. 5.

   Blot S Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care unitsClin Microbiol Infect2008 14513

   Not in our library10.1111/j.1469-0691.2007.01835.x

6. 6.

   Blot S Depuydt P Vandewoude K De Bacquer D Measuring the impact of multidrug resistance in nosocomial infectionCurr Opin Infect Dis2007 20391396

   Not in our library10.1097/qco.0b013e32818be6f7

7. 7.

   Vincent JL Rello J Marshall J Silva E Anzueto A Martin CD Moreno R Lipman J Gomersall C Sakr Y Reinhart K International study of the prevalence and outcomes of infection in intensive care unitsJAMA2009 30223232329

   Not in our library10.1001/jama.2009.1754

8. 8.

   Carlet J Ben Ali A Tabah A Willems V Philippart F Chafine A Garrouste-Orgeas M Misset B Kuhlen R, Moreno R, Ranieri VM, Rhodes AMultidrug resistant infections in the ICU: mechanisms, prevention and treatment25 Years of Progress and Innovation in Intensive Care Medicine2007 Berlin, Germany: Medizinisch Wissenschaftliche Verlagsgesellschaft199211

   Not in our library

9. 9.

   Salgado CD O'Grady N Farr BM Prevention and control of antimicrobial-resistant infections in intensive care patientsCrit Care Med2005 3323732382

   Not in our library10.1097/01.ccm.0000181727.04501.f3

10. 10.

    Cosgrove SE The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costsClin Infect Dis2006 42Suppl 2S82S89

    Not in our library10.1086/499406

11. 11.

    Figueiredo Costa S Impact of antimicrobial resistance on the treatment and outcome of patients with sepsisShock2008 30Suppl 12329

    Not in our library10.1097/shk.0b013e3181818990

12. 12.

    de Kraker ME Wolkewitz M Davey PG Grundmann H Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infectionsAntimicrob Agents Chemother2011 5515981605

    Not in our library10.1128/aac.01157-10

13. 13.

    de Kraker ME Wolkewitz M Davey PG Koller W Berger J Nagler J Icket C Kalenic S Horvatic J Seifert H Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporinsJ Antimicrob Chemother2011 66398407

    Not in our library10.1093/jac/dkq412

14. 14.

    Borg MA Bed occupancy and overcrowding as determinant factors in the incidence of MRSA infections within general ward settingsJ Hosp Infect2003 54316318

    Not in our library10.1016/s0195-6701(03)00153-1

15. 15.

    Clark NM Hershberger E Zervosc MJ Lynch JP Antimicrobial resistance among gram-positive organisms in the intensive care unitCurr Opin Crit Care2003 9403412

    Not in our library10.1097/00075198-200310000-00011

16. 16.

    Bonten MJ Mascini EM The hidden faces of the epidemiology of antibiotic resistanceIntensive Care Med2003 2912

    Not in our library10.1007/s00134-002-1564-3

17. 17.

    Boucher HW Talbot GH Bradley JS Edwards JE Gilbert D Rice LB Scheld M Spellberg B Bartlett J Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaClin Infect Dis2009 48112

    Not in our library10.1086/595011

18. 18.

    Jones RN Resistance patterns among nosocomial pathogens: trends over the past few yearsChest2001 119397S404S

    Not in our library10.1378/chest.119.2_suppl.397s

19. 19.

    National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001Am J Infect Control2001 29404421

    Not in our library10.1067/mic.2001.119952

20. 20.

    Arias CA Contreras GA Murray BE Management of multidrug-resistant enterococcal infectionsClin Microb Infect2010 16555562

    Not in our library10.1111/j.1469-0691.2010.03214.x

21. 21.

    Clark NM Patterson J Lynch JP Antimicrobial resistance among gram-negative organisms in the intensive care unitCurr Opin Crit Care2003 9413423

    Not in our library10.1097/00075198-200310000-00012

22. 22.

    Paterson DL The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter speciesClin Infect Dis2006 43Suppl 2S4348

    Not in our library10.1086/504476

23. 23.

    Goossens H Grabein B Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004)Diagn Microbiol Infect Dis2005 53257264

    Not in our library10.1016/j.diagmicrobio.2005.10.001

24. 24.

    Paterson DL Bonomo RA Extended-spectrum beta-lactamases: a clinical updateClin Microbiol Rev2005 18657686

    Not in our library10.1128/cmr.18.4.657-686.2005

25. 25.

    Pitout JD Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choicesDrugs2010 70313333

    Not in our library10.2165/11533040-000000000-00000

26. 26.

    Cuzon G Naas T Nordmann P [KPC carbapenemases: what is at stake in clinical microbiology?]Pathologie-biologie2010 583945

    Not in our library10.1016/j.patbio.2009.07.026

27. 27.

    Hawser SP Bouchillon SK Hoban DJ Badal RE Hsueh PR Paterson DL Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007Antimicrob Agents Chemother2009 5332803284

    Not in our library10.1128/aac.00426-09

28. 28.

    Brusselaers N Monstrey S Snoeij T Vandijck D Lizy C Hoste E Lauwaert S Colpaert K Vandekerckhove L Vogelaers D Blot S Morbidity and mortality of bloodstream infections in patients with severe burn injuryAm J Crit Care2010 19e8187

    Not in our library10.4037/ajcc2010341

29. 29.

    Jones RN Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001)Sem Respir Crit Care Med2003 24121134

    Not in our library10.1055/s-2003-37923

30. 30.

    Mahgoub S Ahmed J Glatt AE Completely resistant Acinetobacter baumannii strainsInfection Control Hosp Epidemiol2002 23477479

    Not in our library10.1086/502091

31. 31.

    Kincaid SE Clostridium difficile-associated disease: impact of the updated SHEA/IDSA guidelinesConsult Pharm2010 25834836

    Not in our library10.4140/tcp.n.2010.834

32. 32.

    Barbut F Petit JC Epidemiology of Clostridium difficile-associated infectionsClin Microbiol Infect2001 7405410

    Not in our library10.1046/j.1198-743x.2001.00289.x

33. 33.

    Shah D Dang MD Hasbun R Koo HL Jiang ZD DuPont HL Garey KW Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistanceExpert Rev Anti Infect Ther2010 8555564

    Not in our library10.1586/eri.10.28

34. 34.

    Brusselaers N Blot S Vogelaers D Non-blood Candida infections in the ICUNeth J Crit Care2011 in press

    Not in our library

35. 35.

    Miceli MH Diaz JA Lee SA Emerging opportunistic yeast infectionsLancet Infect Dis2011 11142151

    Not in our library10.1016/s1473-3099(10)70218-8

36. 36.

    Chow JK Golan Y Ruthazer R Karchmer AW Carmeli Y Lichtenberg D Chawla V Young J Hadley S Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unitClin Infect Dis2008 4612061213

    Not in our library10.1086/529435

37. 37.

    Leroy O Gangneux JP Montravers P Mira JP Gouin F Sollet JP Carlet J Reynes J Rosenheim M Regnier B Lortholary O Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006)Crit Care Med2009 3716121618

    Not in our library10.1097/ccm.0b013e31819efac0

38. 38.

    Leroy O Mira JP Montravers P Gangneux JP Lortholary O Comparison of albicans vs. non-albicans candidemia in French intensive care unitsCrit Care2010 14R98

    Not in our library10.1186/cc9033

39. 39.

    Holley A Dulhunty J Blot S Lipman J Lobo S Dancer C Rello J Dimopoulos G Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care unitsInt J Antimicrob Agents2009

    Not in our library10.1016/j.ijantimicag.2008.10.035

40. 40.

    Annual epidemiological report on communicable diseases in Europe 2008: Report on the state of communicable diseases in the EU and EEA/EFTA countriesBook Annual epidemiological report on communicable diseases in Europe 2008: Report on the state of communicable diseases in the EU and EEA/EFTA countries2008 European Centre for Disease Prevention and Control

    Not in our library

Cited by papers we hold 1

• Microbial Interdomain Interactions Delineate the Disruptive Intestinal Homeostasis in Clostridioides difficile Infection · 2022
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.